Photo of Yevgeniy Semenov, MD, MA

Yevgeniy Semenov, MD, MA

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-6973
Fax: (617) 724-2745


ysemenov@mgh.harvard.edu

Photo of Yevgeniy Semenov, MD, MA

Massachusetts General Hospital
Phone: (617) 724-6973
Fax: (617) 724-2745


ysemenov@mgh.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Yevgeniy Semenov, MD, MA but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Yevgeniy Semenov, MD, MA

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Dermatology, Harvard Medical School
  • Physician Investigator, Dermatology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Semenov's research aims to integrate large multi-modal clinical and molecular data from patients and tumor samples in developing algorithms and decision support models in cutaneous oncology. To support these efforts, Dr. Semenov has established a robust clinical program at MGH to support these efforts, where he holds an oncodermatology clinic within the Department of Dermatology and an intralesional immunotherapy clinic at the MGH Cancer Center. His research has resulted in important insights into the role of cutaneous immune-related adverse events (irAEs) as early prognostic biomarkers for immunotherapy response and patient survival, particularly in the setting of advanced-stage melanoma. Additionally, as a member of the Severe Immunotherapy Complications service at MGH, Dr. Semenov has been developing a multi-institutional clinical registry and biorepository for the study of immunotherapy toxicities.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Wan G, Leung B, Nguyen N, DeSimone MS, Liu F, Choi MS, Ho D, Laucks V, Duey S, Sullivan RJ, Boland GM, LeBoeuf NR, Liu D, Gusev A, Kwatra SG, Sorger PK, Yu KH, Semenov YR. The impact of stage-related features in melanoma recurrence prediction: A machine learning approach. JAAD Int 2023; 10:28-30. PubMed
  • Stephens MR, Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, Reynolds KL, Sullivan RJ, Foreman RK, Chen ST. Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma. J Am Acad Dermatol 2023. PubMed
  • Leung BW, Collier MR, Tiu BC, Wan G, Nguyen N, Tang K, Zhang S, Chen W, Chen ST, LeBoeuf NR, Semenov YR. Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study. J Am Acad Dermatol 2023. PubMed
  • Asdourian MS, Jacoby TV, Shah N, Otto T, Thompson LL, Dee EC, Reynolds KL, Semenov YR, Chen ST. Non-cutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy. J Am Acad Dermatol 2023. PubMed
  • Chen W, Wan G, Nguyen N, Leung B, Wen J, Collier MR, Kwatra SG, Semenov YR. Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration. JAAD Int 2022; 9:112-115. PubMed
  • Wan G, Nguyen N, Liu F, DeSimone MS, Leung BW, Rajeh A, Collier MR, Choi MS, Amadife M, Tang K, Zhang S, Phillipps JS, Jairath R, Alexander NA, Hua Y, Jiao M, Chen W, Ho D, Duey S, Németh IB, Marko-Varga G, Valdés JG, Liu D, Boland GM, Gusev A, Sorger PK, Yu KH, Semenov YR. Prediction of early-stage melanoma recurrence using clinical and histopathologic features. NPJ Precis Oncol 2022; 6:79. PubMed
  • Sutaria N, Alphonse MP, Roh YS, Choi J, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Pritchard T, Kim N, Aguh C, Semenov YR, Archer NK, Garza LA, Kang S, Kwatra SG. Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. J Invest Dermatol 2022; 142:2537-2540. PubMed
  • Asdourian MS, Shah N, Jacoby TV, Semenov YR, Otto T, Thompson LL, Dee EC, Reynolds KL, Chen ST. Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade. J Am Acad Dermatol 2022. PubMed
  • Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, LeBoeuf NR, Reynolds KL, Dewan AK, Chen ST. Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anti-cancer therapies: a multicenter retrospective study. J Am Acad Dermatol 2022. PubMed
  • Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P, Seo J, Tang K, Sise ME, Sullivan R, Naidoo J, Mooradian MJ, Semenov YR, Reynolds KL. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer 2022. PubMed
  • Le TK, Brown I, Goldberg R, Taylor MT, Deng J, Parthasarathy V, Bordeaux ZA, Alphonse MP, Kwatra MM, Naranbhai V, Gusev A, Alhariri J, LeBoeuf NR, Reynolds KL, Cappelli LC, Naidoo J, Brahmer JR, Kang S, Semenov YR, Kwatra SG. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol 2022. PubMed
  • Asdourian MS, Shah N, Jacoby TV, Thompson LL, Otto T, Semenov YR, Reynolds KL, Chen ST. Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. J Am Acad Dermatol 2022. PubMed
  • Gopinath S, Sutaria N, Bordeaux ZA, Parthasarathy V, Deng J, Taylor MT, Marani M, Lee K, Pritchard T, Alajmi A, Adawi W, Oladipo OO, Semenov YR, Alphonse M, Kwatra SG. Reduced serum pyridoxine and 25-hydroxyvitamin D levels in adults with chronic pruritic dermatoses. Arch Dermatol Res 2022. PubMed
  • Le TK, Kaul S, Cappelli LC, Naidoo J, Semenov YR, Kwatra SG. Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. J Dermatolog Treat 2022; 33:1691-1695. PubMed
  • Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens MR, Estiri H, Lilly E, Asgari M, Semenov YR. Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated". J Am Acad Dermatol 2022. PubMed
  • Parthasarathy V, Pollock JR, McNeely GL, Hogan JS, Bordeaux ZA, Trinh P, Deng J, Swanson DL, Sharfstein JM, Semenov YR, Kwatra SG. A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020. Arch Dermatol Res 2022. PubMed
  • Tang K, Tiu BC, Wan G, Zhang S, Nguyen N, Leung B, Gusev A, Reynolds KL, Kwatra SG, Semenov YR. Pre-Existing Autoimmune Disease and Mortality in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy. Journal of the National Cancer Institute 2022. PubMed
  • Asdourian MS, Otto TS, Jacoby TV, Shah N, Thompson LL, Blum SM, Reynolds KL, Semenov YR, Lawrence DP, Sullivan RJ, Boland GM, Villani AC, Chen ST. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. J Am Acad Dermatol 2022. PubMed
  • Sutaria N, Marani M, Choi J, Roh YS, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Lee KK, Pritchard T, Alajmi A, Adawi W, Semenov YR, Alphonse MP, Kwatra SG. Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis. J. Dermatol. Sci. 2022; 105:130-136. PubMed
  • Choi J, Sutaria N, Roh YS, Bordeaux Z, Sweren RJ, Semenov YR, Kwatra SG. Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides: A cross-sectional analysis of the 2012-2017 National Inpatient Sample. J Am Acad Dermatol 2022; 86:1408-1410. PubMed
  • Wongvibulsin S, Parthasarathy V, Pahalyants V, Murphy W, Sutaria N, Roh YS, Bordeaux ZA, Deng J, Taylor MT, Semenov YR, Kwatra SG. Latent class analysis identification of prurigo nodularis comorbidity phenotypes. Br J Dermatol 2022; 186:903-905. PubMed
  • Said JT, Liu M, Talia J, Singer SB, Semenov YR, Wei EX, Mostaghimi A, Nelson CA, Giobbie-Hurder A, LeBoeuf NR. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors. JAMA Dermatol 2022; 158:552-557. PubMed
  • Tang K, Seo J, Tiu BC, Le TK, Pahalyants V, Raval NS, Ugwu-Dike PO, Zubiri L, Naranbhai V, Carrington M, Gusev A, Reynolds KL, LeBoeuf NR, Asgari MM, Kwatra SG, Semenov YR. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol 2022; 158:189-193. PubMed
  • Sutaria N, Semenov YR, Kwatra SG. Understanding racial disparities in prurigo nodularis. J Am Acad Dermatol 2022; 87:e111-e112. PubMed
  • Deng J, Parthasarathy V, Adawi W, Bordeaux Z, Sutaria N, Gami A, Taylor M, Lee KK, Marani M, Brown I, Kambala A, Cornman HL, Alajmi A, Pritchard T, Oladipo OO, Semenov YR, Kwatra SG. Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus. JAMA Dermatol 2022; 158:791-795. PubMed
  • Roh YS, Marani M, Choi U, Sutaria N, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Semenov YR, Kwatra SG. Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis. J Am Acad Dermatol 2022; 87:482-484. PubMed
  • Sutaria N, Adawi W, Brown I, Parthasarathy V, Roh YS, Choi J, Bordeaux ZA, Trinh P, Le TK, Deng J, Semenov YR, Kwatra SG. Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study. J Am Acad Dermatol 2022; 86:487-490. PubMed
  • Sutaria N, Alphonse MP, Marani M, Parthasarathy V, Deng J, Wongvibulsin S, Williams K, Roh YS, Choi J, Bordeaux Z, Pritchard T, Dillen C, Semenov YR, Kwatra MM, Archer NK, Garza LA, Dong X, Kang S, Kwatra SG. Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans. J Invest Dermatol 2022; 142:1300-1308.e3. PubMed
  • Gil J, Rezeli M, Lutz EG, Kim Y, Sugihara Y, Malm J, Semenov YR, Yu KH, Nguyen N, Wan G, Kemény LV, Kárpáti S, Németh IB, Marko-Varga G. An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation. Cancers (Basel) 2021. PubMed
  • Raval NS, Hodges WT, Ugwu-Dike PO, Godoy F, Ansstas G, Cornelius LA, Musiek AC, Asgari MM, Semenov YR. Racial and socioeconomic differences in acral lentiginous melanoma outcomes: A Surveillance, Epidemiology, and End Results analysis. J Am Acad Dermatol 2021. PubMed
  • Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens RM, Estir H, Lilly E, Asgari M, Semenov YR. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts. J Am Acad Dermatol 2021. PubMed
  • Rosenberg AR, Weston SJ, Deshields T, Fields RC, Linette GP, Cornelius LA, Semenov YR. Health-related quality of life in patients with malignant melanoma by stage and treatment status. J Am Acad Dermatol 2021; 85:486-489. PubMed
  • Estiri H, Strasser ZH, Brat GA, Semenov YR, , Patel CJ, Murphy SN. Evolving Phenotypes of non-hospitalized Patients that Indicate Long Covid. medRxiv 2021. PubMed
  • Phelan PS, Semenov YR, Nahmias ZP. Worldwide seasonal variation in search volume for cutaneous warts from 2004 to 2019. J Am Acad Dermatol 2021; 84:1417-1419. PubMed
  • Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol 2021. PubMed
  • Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist 2021. PubMed
  • Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer 2021. PubMed
  • Osemwota O, Herbosa CM, Zhong C, Kwatra SG, Kim BS, Semenov YR. Ethnic variations in scalp pruritus and hair loss. J Am Acad Dermatol 2021; 84:792-794. PubMed
  • Gusev A, Groha S, Taraszka K, Semenov YR, Zaitlen N. Constructing germline research cohorts from the discarded reads of clinical tumor sequences. Genome Med 2021; 13:179. PubMed
  • Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer 2021. PubMed
  • Semenov YR, Herbosa CM, Rogers AT, Huang A, Kwatra SG, Cohen B, Anadkat MJ, Silverberg JI. Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey. J Am Acad Dermatol 2021; 85:396-403. PubMed
  • Estiri H, Strasser ZH, Brat GA, Semenov YR, , Patel CJ, Murphy SN. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med 2021; 19:249. PubMed
  • Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist 2021; 26:e898-e901. PubMed
  • Wongvibulsin S, Sutaria N, Williams KA, Huang AH, Choi J, Roh YS, Hong M, Kelley D, Pahalyants V, Murphy W, Alphonse MP, Bakhshi P, Walia A, Semenov YR, Kwatra SG. A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States. J Invest Dermatol 2021; 141:2530-2533.e1. PubMed
  • Zhang J, Erickson S, Semenov YR, Council ML. Surgical Outcomes and Risk Factors for Apical Triangle Basal Cell Carcinomas: A Single Institution Analysis. Dermatol Surg 2021; 47:1125-1127. PubMed
  • Herbosa CM, Bhat TS, Semenov YR, Rosman IS, Musiek AC. Diagnostic concordance of clinical diagnosis, tissue culture, and histopathology testing for skin and soft tissue infections: A single-center retrospective study. Int J Womens Dermatol 2020; 6:395-398. PubMed
  • Kwatra SG, Hines H, Semenov YR, Trotter SC, Holland E, Leachman S. A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma. J Clin Aesthet Dermatol 2020; 13:s3-s14. PubMed
  • Almazan E, Roh YS, Belzberg M, Qin CX, Williams K, Choi J, Sutaria N, Kaffenberger B, Semenov YR, Alhariri J, Kwatra SG. Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study. Medicines (Basel) 2020. PubMed
  • Bigelow RT, Semenov YR, Hoffman HJ, Agrawal Y. Association between vertigo, cognitive and psychiatric conditions in US children: 2012 National Health Interview Survey. Int. J. Pediatr. Otorhinolaryngol. 2020; 130:109802. PubMed
  • Kwatra SG, Boozalis E, Huang AH, Nanni C, Khanna R, Williams KA, Semenov YR, Roberts CM, Burns RF, Krischak M, Kwatra MM. Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. Medicines (Basel) 2019. PubMed
  • Huang AH, Kwatra SG, Khanna R, Semenov YR, Okoye GA, Sweren RJ. Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. J Natl Med Assoc 2019; 111:633-639. PubMed
  • Semenov YR, Hsiang EY, Huang A, Herbosa CM, Hui X, Kwatra SG, Cohen B, Anadkat MJ. Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. J Rheumatol 2019; 46:587-594. PubMed
  • Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S, Kang S, Kwatra SG. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 2018; 79:714-719.e3. PubMed
  • Boozalis E, Semenov YR, Kwatra SG. Food and drug administration approval process for dermatology drugs in the United States. J Dermatolog Treat 2018; 29:536-538. PubMed
  • Rogers AT, Semenov YR, Kwatra SG, Okoye GA. Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey, 2005-2014. J Dermatolog Treat 2018; 29:287-289. PubMed
  • Agrawal Y, Pineault KG, Semenov YR. Health-related quality of life and economic burden of vestibular loss in older adults. Laryngoscope Investig Otolaryngol 2018; 3:8-15. PubMed
  • Grandhi R, He A, Semenov YR, Kwatra SG. Seasonal variation of itch: A study using real-time data from 2004 to 2016. J Am Acad Dermatol 2017; 76:563-564. PubMed
  • Crowson MG, Semenov YR, Tucci DL, Niparko JK. Quality of Life and Cost-Effectiveness of Cochlear Implants: A Narrative Review. Audiol. Neurootol. 2017; 22:236-258. PubMed
  • Bigelow RT, Semenov YR, Anson E, du Lac S, Ferrucci L, Agrawal Y. Impaired Vestibular Function and Low Bone Mineral Density: Data from the Baltimore Longitudinal Study of Aging. J Assoc Res Otolaryngol 2016; 17:433-40. PubMed
  • Bigelow RT, Semenov YR, du Lac S, Hoffman HJ, Agrawal Y. Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey. J Neurol Neurosurg Psychiatry 2016; 87:367-72. PubMed
  • Semenov YR, Bigelow RT, Xue QL, du Lac S, Agrawal Y. Association Between Vestibular and Cognitive Function in U.S. Adults: Data From the National Health and Nutrition Examination Survey. J Gerontol A Biol Sci Med Sci 2016; 71:243-50. PubMed
  • Bigelow RT, Semenov YR, Trevino C, Ferrucci L, Resnick SM, Simonsick EM, Xue QL, Agrawal Y. Association Between Visuospatial Ability and Vestibular Function in the Baltimore Longitudinal Study of Aging. J Am Geriatr Soc 2015; 63:1837-44. PubMed
  • Harun A, Clark J, Semenov YR, Francis HW. The Role of Obliteration in the Achievement of a Dry Mastoid Bowl. Otol. Neurotol. 2015; 36:1510-7. PubMed
  • Sun DQ, Ward BK, Semenov YR, Carey JP, Della Santina CC. Bilateral Vestibular Deficiency: Quality of Life and Economic Implications. JAMA Otolaryngol Head Neck Surg 2014; 140:527-34. PubMed
  • Chan JY, Semenov YR, Gourin CG. Postoperative urinary tract infection and short-term outcomes and costs in head and neck cancer surgery. 2013; 148:602-10. PubMed
  • Semenov YR, Martinez-Monedero R, Niparko JK. Cochlear implants: clinical and societal outcomes. Otolaryngol. Clin. North Am. 2012; 45:959-81. PubMed
  • Hennessey P, Semenov YR, Gourin CG. The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope 2012; 122:2199-204. PubMed
  • Semenov YR, Starmer HM, Gourin CG. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope 2012; 122:1994-2004. PubMed
  • Semenov YR, Yeh ST, Seshamani M, Wang NY, Tobey EA, Eisenberg LS, Quittner AL, Frick KD, Niparko JK, . Age-dependent cost-utility of pediatric cochlear implantation. ; 34:402-12. PubMed
  • Harun A, Semenov YR, Agrawal Y. Vestibular Function and Activities of Daily Living: Analysis of the 1999 to 2004 National Health and Nutrition Examination Surveys. Gerontol Geriatr Med . PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Yevgeniy Semenov, MD, MA but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members